Literature DB >> 33128167

TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.

Zhi-Han Li1,2, Lei Lei1, Liang-Ru Fei1, Wen-Jing Huang1, Yi-Wen Zheng1, Mai-Qing Yang1, Zhao Wang1, Chen-Chen Liu1, Hong-Tao Xu3.   

Abstract

Thyroid hormone receptor interactor 13 (TRIP13) is an ATPase that has been found to be overexpressed in many tumors. The aim of this study was to investigate the role of TRIP13 and its mechanism of action in lung cancer. The expression of TRIP13 was examined in lung cancer tissues and corresponding normal lung tissues by western blotting. TRIP13 was overexpressed or knocked down by transient transfection or siRNA interference in lung cancer cells, respectively. The expression of key proteins associated with the Wnt signaling pathway and epithelial-mesenchymal transition (EMT) was assessed. The interaction between TRIP13 and low-density lipoprotein receptor-related protein 6 (LRP6) was examined by co-immunoprecipitation and laser confocal immunofluorescence. Moreover, this study determined the proliferative and invasive ability of cells through colony formation, cell proliferation, and Matrigel invasion assays. The expression of TRIP13 was higher in lung cancer tissues than in normal lung tissues (p = 0.002), and this correlated with poor patient prognosis (p < 0.001). In addition, overexpression of TRIP13 enhanced the levels of active β-catenin and target proteins of the Wnt signaling pathways (p < 0.05). This study found that TRIP13 can co-localize and bind with LRP6. Furthermore, overexpression of TRIP13 caused the upregulation of N-cadherin, Snail, and vimentin, and the downregulation of E-cadherin (p < 0.05). The aforementioned results were reversed after knocking down the expression of TRIP13 (p < 0.05). TRIP13 is highly expressed in lung cancers, indicating poor prognosis. overexpression of TRIP13 promotes the proliferative and invasive ability of lung cancer cells via the activation of Wnt signaling pathway and EMT.

Entities:  

Keywords:  Cell proliferation; Epithelial-mesenchymal transition; Lung neoplasms; Neoplasm invasiveness; TRIP13; Wnt signaling pathway

Year:  2020        PMID: 33128167     DOI: 10.1007/s10735-020-09919-z

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  22 in total

1.  Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction.

Authors:  Gary Davidson; Wei Wu; Jinlong Shen; Josipa Bilic; Ursula Fenger; Peter Stannek; Andrei Glinka; Christof Niehrs
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

2.  Upregulation of Wnt signaling under hypoxia promotes lung cancer progression.

Authors:  Chun-Fu Hong; Wei-You Chen; Cheng-Wen Wu
Journal:  Oncol Rep       Date:  2017-07-12       Impact factor: 3.906

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

5.  TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.

Authors:  Liming Dong; Honglin Ding; Yanpei Li; Dongwei Xue; Zhi Li; Yili Liu; Teng Zhang; Jian Zhou; Ping Wang
Journal:  Int J Biol Macromol       Date:  2018-09-26       Impact factor: 6.953

6.  Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.

Authors:  Wei Li; Gengyan Zhang; Xiaojun Li; Xiaojing Wang; Qing Li; Lei Hong; Yuangbing Shen; Chenling Zhao; Xiaomeng Gong; Yuqing Chen; Jihong Zhou
Journal:  Biochem Biophys Res Commun       Date:  2018-03-30       Impact factor: 3.575

7.  Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer.

Authors:  Ji Un Kang; Sun Hoe Koo; Kye Chul Kwon; Jong Woo Park; Jin Man Kim
Journal:  Cancer Genet Cytogenet       Date:  2008-04-01

8.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

Review 9.  Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Authors:  Fengzhi Li; Ieman Aljahdali; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

10.  TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.

Authors:  Rajat Banerjee; Nickole Russo; Min Liu; Venkatesha Basrur; Emily Bellile; Nallasivam Palanisamy; Christina S Scanlon; Elizabeth van Tubergen; Ronald C Inglehart; Tarek Metwally; Ram-Shankar Mani; Anastasia Yocum; Mukesh K Nyati; Rogerio M Castilho; Sooryanarayana Varambally; Arul M Chinnaiyan; Nisha J D'Silva
Journal:  Nat Commun       Date:  2014-07-31       Impact factor: 14.919

View more
  2 in total

1.  Construction and analysis of the ceRNA network hsa_circ_0031968/miR-3611/GCG in lung adenocarcinoma.

Authors:  Yang Yang; Yuan Zhang; Xuqing Ding; Yukai Ren; Bochong Wei; Zongxiang Lin; Yunfei Nie; Yuxia Fan
Journal:  Ann Transl Med       Date:  2021-12

2.  KIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathway.

Authors:  Lan Liu; Zhaofeng Zhang; Xiulin Xia; Jing Lei
Journal:  Oncol Lett       Date:  2022-02-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.